Steven Lo compensation by year
PUMA BIOTECHNOLOGY Summary Compensation Table · all 4 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|
| Salary | $435,625 | $455,261 | $468,918 | $468,507 |
| Bonus | $270,143 | $200,314 | $206,324 | $0 |
| Stock awards | $1,712,025 | $0 | $0 | $0 |
| Option awards | $649,195 | $738,193 | $1,548,743 | $792,034 |
| Non-equity incentive | $0 | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $14,206 | $12,502 | $12,291 | $57,438 |
| Total | $3,081,194 | $1,406,270 | $2,236,276 | $1,317,979 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: PUMA BIOTECHNOLOGY, INC. DEF 14A filed April 27, 2020, accession 0001193125-20-120969, and prior-year filings. Open the filing on EDGAR.
How this page was built: the PUMA BIOTECHNOLOGY, INC. filed document, accession 0001193125-20-120969. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2020.
PUMA BIOTECHNOLOGY’s named executive officers, FY2019
as the company reported each| Named executive officer | Role | FY2019 total |
|---|---|---|
| Alan Auerbach | President and Chief Executive Officer | $3,755,322 |
| Douglas Hunt | Senior Vice President, Regulatory Affairs, Medical Writing and Project Management | $1,378,387 |
| MBChB Richard P. Bryce | Senior Vice President, Clinical Research and Development | $1,331,139 |
| Steven Lo · this page | Chief Commercial Officer | $1,317,979 |
| Maximo Nougues | Chief Financial Officer | $665,799 |
The full PUMA BIOTECHNOLOGY compensation record
free company briefThis page is one person within PUMA BIOTECHNOLOGY's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the PUMA BIOTECHNOLOGY proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are PUMA BIOTECHNOLOGY's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.